Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Starmab biologics(Shanghai)Co,.ltd
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description

Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Pneumococcal Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
XJ103-I | P1 |
Active, not recruiting |
Pneumococcal Infections |
2024-12-24 |